INDUSTRY

INSTITUTIONAL RESEARCH

Marico

NEUTRAL

FMCG

Copra deflation saves the day

Marico disappointed on volume growth owing to rural slowdown. Hair oil category growth was sluggish in 2Q. Copra deflation and international performance drove healthy EBITDA growth. We recently downgraded Marico to NEUTRAL as RM tailwinds are expected to moderate and near-term positives were priced-in. We value Marico at 35x on Sep-21 EPS arriving at a TP of Rs 391.

HIGHLIGHTS OF THE QUARTER

- Consol. revenue growth was flat (exp. 6.6%) with 6% volume growth. Domestic revenue/volume grew at -3/1% (20/6% in 2QFY19) vs. our exp of 6/6%. International biz grew by 8/9% value/cc growth led by Bangladesh (15%). Urban GT/Rural growth declined by 11/3%. Modern trade was up 29%, resulting in 3% overall growth in Urban.
- PCNO grew by -4/-1% value/volume owing to a high base (32/8%) and sluggish growth in rural. PCNO gained a handsome market share of 225bps as its offtake growth was healthy. Copra prices are down 10% YoY in 2Q. Marico is passing on value via promotions instead of price cuts. Copra prices are expected to increase moderately on a QoQ basis. We believe RM tailwinds will begin moderating from 4Q.
- VAHO's performance was disappointing as it degrew by 6%. Liquidity stress, rural slowdown and sluggish category growth impacted growth. <u>Distribution initiatives and</u>

brand franchise are driving market share gains (up 100bps to 35% vol. share).

- Saffola oil grew by 5/1% in value/volume terms. Saffola's recovery remains a struggle despite various initiatives. Management continues to rely on its 'trial and failure' strategy by varying promotions across channels. However, Saffola foods grew by 39% led by aggressive new launches.
- GM expanded by 565bps (exp 370bps) making it the sharpest expansion in this copra cycle. A&P spends (12% growth) were modest resulting in 263bps adj. EBITDAM expansion (exp. 169bps). India/international EBIT grew by 10/25% growth.

STANCE

The stock re-rated in the last 3-4 quarters owing to superior EBITDA growth. Marico was our top-pick 12 months back when copra cycle was expected to reverse. We recently downgraded Marico to NEUTRAL as we believe peak copra deflationary cycle is now behind. We expect tailwinds from deflation in input costs to moderate over the next 2 quarters. As a result, most of the positives are priced-in (30% run up in the last 12-months). The stock does not deserve a further re-rating as new launches are not moving the needle and core biz volume growth remains tepid.

CMP (as on 25 O	ct 201 9))	Rs 393				
Target Price			Rs 391				
Nifty			11,584				
Sensex			39,058				
KEY STOCK DATA							
Bloomberg		N	IRCO IN				
No. of Shares (mn))		1,291				
MCap (Rs bn) / (\$	mn)	50	8/7,159				
6m avg traded val	ue (Rs n	nn)	735				
STOCK PERFORMA	ANCE (%	5)					
52 Week high / lo	w	Rs 4	04/295				
	3M	6M	12M				
Absolute (%)	8.8	10.4	32.2				
Relative (%)	5.6	9.5	16.3				
SHAREHOLDING P	ATTERN	ı (%)					
	Jun	-19	Sep-19				
Promoters	59	.70	59.60				
FIs & Local MFs	5	5.79	8.63				
FPIs	25	5.72	24.90				
Public & Others	8	3.79	6.87				
Pledged Shares	C	0.00	0.00				
Source : BSE							
Jource . DJL							

Financial Summary

YE March (Rs mn)	2QFY20	2QFY19	YoY (%)	1QFY20	QoQ (%)	FY18	FY19	FY20E	FY21E	FY22E
Net Revenues	18,290	18,368	(0.4)	21,660	(15.6)	63,222	73,336	77,799	86,667	95,803
EBITDA	3,530	2,941	20.0	4,610	(23.4)	11,378	12,809	15,831	18,173	20,378
APAT	2,470	2,142	15.3	3,224	(23.4)	8,142	9,309	11,247	13,241	15,254
Diluted EPS (Rs)	1.91	1.66	15.3	2.50	(23.4)	6.31	7.21	8.71	10.26	11.82
P/E (x)						62.6	54.8	45.3	38.5	33.4
EV / EBITDA (x)						44.9	39.7	32.0	28.1	25.1
Core RoCE (%)						40.6	48.8	47.5	52.9	57.7

Source: Company, HDFC sec Inst Research

Naveen Trivedi

naveen.trivedi@hdfcsec.com +91-22-6171-7324

Siddhant Chhabria

siddhant.chhabria@hdfcsec.com +91-22-6171-7336 Consol. revenue growth was flat (exp. 6.6%) with 6% volume growth

Domestic revenue/volume grew at -3/1% (20/6% in 2QFY19) vs. our exp of 6/6%.

India/International revenues grew by -3/8% while EBIT grew by 10/25% respectively

GM expanded by 565bps (exp 370bps) making it the sharpest expansion in this copra cycle. Copra deflation during 2QFY20 was 10% YoY

A&P spends (12% growth) were modest resulting in 263bps adj. EBITDAM expansion (exp. 169bps).

Quarterly Financials

Year to March (Rs mn)	2QFY20	2QFY19	YoY (%)	1QFY20	QoQ (%)	FY19	FY18	YoY (%)
Net Revenue	18,290	18,368	(0.4)	21,660	(15.6)	73,340	63,220	16.0
Material Expenses	9,210	10,287	(10.5)	11,370	(19.0)	40,170	33,480	20.0
Employee Expenses	1,270	1,146	10.9	1,270	-	4,660	4,220	10.4
ASP Expenses	1,970	1,758	12.0	2,190	(10.0)	6,590	5,880	12.1
Other Expenses	2,310	2,237	3.3	2,220	4.1	9,110	8,270	10.2
EBITDA	3,530	2,941	20.0	4,610	(23.4)	12,810	11,370	12.7
EBITDA (IND-AS 116)	3,410	2,941	16.0	4,610	(26.0)	12,810	11,370	12.7
Depreciation	350	224	56.3	350	-	960	890	7.9
EBIT	3,180	2,717	17.1	4,260	(25.4)	11,850	10,480	13.1
Other Income	350	292	19.8	280	25.0	1,030	850	21.2
Interest Cost	130	57	129.3	120	8.3	240	160	50.0
PBT	3,400	2,952	15.2	4,230	(19.6)	12,630	11,170	13.1
Tax	880	776	13.4	1,080	(18.5)	1,280	2,900	(55.9)
PAT	2,470	2,142	15.3	3,080	(19.8)	11,182	8,142	37.3
Exceptional Items	-	-	na	144	na	(1,873)	-	na
APAT	2,470	2,142	15.3	3,224	(23.4)	9,309	8,142	14.3
EPS	1.9	1.7	15.3	2.5	(23.4)	7.2	6.3	14.3

As % Of Net Revenue	2QFY20	2QFY19	YoY (bps)	1QFY20	QoQ (bps)	FY19	FY18	YoY (bps)
Material Expenses	50.4	56.0	(565)	52.5	(214)	54.8	53.0	181
Employee Expenses	6.9	6.2	71	5.9	108	6.4	6.7	(32)
A&P Expenses	10.8	9.6	120	10.1	66	9.0	9.3	(32)
Other Expenses	12.6	12.2	45	10.2	238	12.4	13.1	(66)
EBITDA Margin (%)	19.3	16.0	329	21.3	(198)	17.5	18.0	(52)
Adj EBITDA Margin (%)	18.6	16.0	263	21.3	(264)	31.9	18.0	1,390
Tax Rate (%)	25.9	26.3	(41)	25.5	35	10.1	26.0	(1,583)
APAT Margin (%)	13.5	11.7	184	14.9	(138)	12.7	12.9	(19)

Domestic value growth was lower than volume growth owing to higher promotions in PCNO portfolio

International business continued to recover with 9% cc growth

Quarterly Segmental

Year to March (Rs mn)	2QFY20	2QFY19	YoY (%)	1QFY20	QoQ (%)	FY19	FY18	YoY (%)
Segmental Revenues								
Domestic	13,980	14,389	(2.8)	17,310	(19.2)	57,560	49,690	15.8
International	4,310	3,980	8.3	4,350	(0.9)	15,780	13,640	15.7
Total	18,290	18,368	(0.4)	21,660	(15.6)	73,340	63,330	15.8
Segmental EBIT								
Domestic	2,690	2,457	9.5	3,650	(26.3)	10,680	10,040	6.4
International	880	705	24.8	1,060	(17.0)	2,890	2,100	37.6
Total	3,570	3,162	12.9	4,710	(24.2)	13,570	12,140	11.8
Capital Employed								
Domestic	12,740	12,401	2.7	11,910	7.0	13,920	13,013	7.0
International	6,870	7,670	(10.4)	7,020	(2.1)	6,930	7,475	(7.3)
Total	19,610	20,071	(2.3)	18,930	3.6	20,850	20,488	1.8

Source: Company, HDFC sec Inst Research

EBIT Margin

Year to March (Rs mn)	2QFY20	2QFY19	YoY (bps)	1QFY20	QoQ (bps)	FY19	FY18	YoY (bps)
EBIT Margin (%)								
Domestic	19.2	17.1	217	21.1	(184)	18.6	20.2	(165)
International	20.4	17.7	270	24.4	(395)	18.3	15.4	292
Total	19.5	17.2	231	21.7	(223)	18.5	19.2	(67)

Source: Company, HDFC sec Inst Research

Business Performance

Value Growth (%)	3QFY17	4QFY17	1QFY18	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20
Total	(7)	2	(4)	6	15	12	20	20	15	9	7	-
India	(9)	6	(4)	12	19	12	23	20	13	7	6	(3)
International	-	(8)	(1)	(8)	1	13	9	18	21	14	9	8

Parachute performance has been remarkable in the last 18 months

Saffola remains a WIP

VAHO's performance in 2Q was weak owing to rural slowdown and sluggish category growth

More than 80% of the portfolio gained market share

Segment Performance

Particulars (%)	3QFY17	4QFY17	1QFY18	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20
FMCG Business (India)												
Value Growth	(9)	6	(4)	12	19	12	23	20	13	7	6	(3)
Volume Growth	(4)	10	(9)	8	9	1	12	6	5	8	6	1
Parachute Coconut Oil												
Value Growth	(12)	11	3	26	41	24	38	32	19	4	8	(4)
Volume Growth	(1)	15	(9)	12	15	-5	9	8	9	6	9	(1)
VAHO												
Value Growth	(13)	9	(7)	12	7	9	12	12	19	7	11	(6)
Volume Growth	(12)	10	(8)	12	8	11	15	5	7	1	7	-
Saffola (Refined Edible Oil)												
Value Growth	7	3	(8)	1	(4)	(3)	9	9	8	15	6	5
Volume Growth	6	6	(9)	3	0	-1	10	5	2	18	3	1

Source: Company, HDFC sec Inst Research

Market Share Trend

Double Love (0/)	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q
Particulars (%)	FY17	FY17	FY18	FY18	FY18	FY18	FY19	FY19	FY19	FY19	FY20	FY20
India												
Coconut Oils	58	58	58	59	59	59	59	59	59	59	60	60
Saffola	65	66	66	67	68	69	70	71	72	73	73	75
Value added Hair Oils	33	33	33	34	34	34	34	34	34	34	34	35
Livon and Silk & Shine	81	82	83	83	83	82	81	78	76	75	63	64
Hair Creams/Gels	63	63	62	62	63	63	63	62	61	60	60	na
Saffola Oats	28	27	27	27	28	28	29	29	29	29	30	31
Overseas												
VAHO (Bangladesh)	17	18	18	20	21	21	21	22	23	23	22	22
PCNO (Bangladesh)	85	86	86	87	87	87	87	87	87	86	84	84
X-Men Men's Shampoo (Vietnam)	37	37	38	39	40	39	39	39	40	39	38	37
Hair Code & Fiancée (Egypt)	54	54	54	54	53	53	na	na	na	na	na	na




Bangladesh continues to outperform as the co is focusing on driving growth in VAHO as PCNO portfolio matures

Geographical Performance (Constant Currency Growth)

Geographies	3QFY17	4QFY17	1QFY18	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20
Bangladesh	-	5	12	11	12	17	9	10	16	12	11	15
MENA	(27)	(46)	(14)	-	15	61	17	19	8	5	~(10)	(3)
South Africa	4	6	5	1	32	32	7	18	0	3	6	(2)
South East Asia	6	11	7	(8)	(4)	(3)	0	14	13	4	8	1


Source: Company, HDFC sec Inst Research

Consolidated Revenue Breakup (FY19)



Source: Company, HDFC sec Inst Research


International Revenue Breakup (FY19)



Urban GT/Rural growth declined by 11/3%. Modern trade was up 29%, resulting in 3% overall growth in Urban.


Modern trade is now 15% of domestic turnover, and continues to grow in high double digits

Urban GT Growth (YoY)




Source: Company, HDFC sec Inst Research

Rural Growth (YoY)




Source: Company, HDFC sec Inst Research

Modern Trade Growth (YoY)



Source: Company, HDFC sec Inst Research

CSD Growth (YoY)






Copra prices are down 10% YoY

PCNO pricing is stagnant.


Management is passing value in the form of promotions

Change in Raw Material Prices




Note: Jun-18 prices are indexed to 100 Source: Company, HDFC sec Inst Research

Change in Product MRP




Note: Jun-18 prices are indexed to 100 Source: Company, HDFC sec Inst Research

Copra Inflation (YoY %)



Source: Company, HDFC sec Inst Research

Gross Margin Change





Management guided for 8-10% volume growth for the domestic business in the medium term and double digit cc growth for international business

We bake in higher ASP spend in the medium-long term to support new product launches

We cut earnings to factor in moderation in sector growth and GM expansion (copra cycle tailwinds will moderate in next 2 quarters).

Assumptions

Year to March (Rs mn)	FY17	FY18	FY19	FY20E	FY21E	FY22E
Revenue Growth (%)						
Domestic Business	(2.1)	8.6	15.9	4.9	11.5	10.3
Parachute Coconut	(11.6)	10.0	23.0	3.1	9.5	8.0
VAHO	6.8	10.6	12.2	4.0	10.7	10.0
Saffola Oil	6.1	(3.9)	10.0	5.7	9.0	9.0
IBD	2.0	2.0	10.0	18.0	20.0	20.0
Gross Margin (%)	52.2	47.0	45.5	52.5	49.2	49.1
ASP (% of sales)	11.0	9.3	9.0	10.0	10.0	9.9
Distribution (% of sales)	4.0	3.8	4.0	4.0	4.0	4.0
EBITDA Margin (%)	19.6	18.0	17.5	20.3	21.0	21.3
Tax Rate (%)	29.4	25.9	10.2	24.7	25.0	25.0

Source: Company, HDFC sec Inst Research

Estimate change

		FY20E			FY21E		FY22E			
	New	Old	Chg (%)	New	Old	Chg (%)	New	Old	Chg (%)	
Sales	77,799	79,623	(2.3)	86,667	89,170	(2.8)	95,803	100,260	(4.4)	
EBITDA	15,831	15,891	(0.4)	18,173	18,399	(1.2)	20,378	21,096	(3.4)	
PAT	11,247	11,221	0.2	13,241	13,420	(1.3)	15,254	15,777	(3.3)	
EPS	8.7	8.7	0.2	10.3	10.4	(1.3)	11.8	12.2	(3.3)	

Source: HDFC sec Inst Research



Peer Set Comparison

	MCap (Rs bn)	CMP (Rs)	Reco.	TP (Rs)	EPS (Rs)		P/E (x)		EV/EBITDA (x)			Core RoCE (%)				
Company					FY19	FY20E	FY21E	FY19	FY20E	FY21E	FY19	FY20E	FY21E	FY19	FY20E	FY21E
HUL	4,569	2,145	NEU	2,017	28.1	34.3	42.2	76.2	62.5	50.9	51.5	46.5	35.9	248.6	38.7	28.0
ITC	2,790	249	BUY	368	10.4	12.9	14.0	23.9	19.2	17.8	15.1	13.7	12.2	39.2	46.3	49.1
Nestle	1,427	14,803	NR	13,640	167.1	233.6	278.1	88.6	63.4	53.2	51.3	44.0	37.7	82.1	114.7	137.3
Dabur	828	470	BUY	490	8.2	9.5	11.4	57.3	49.3	41.2	46.1	39.6	34.2	50.1	52.9	58.3
Britannia	788	3,283	BUY	3,594	48.1	58.6	71.9	68.3	56.0	45.7	44.7	40.5	33.1	39.2	43.1	49.8
Marico	508	395	NEU	391	7.2	8.7	10.3	54.8	45.3	38.5	39.7	32.0	28.1	48.8	47.5	52.9
Colgate	413	1,519	NEU	1,400	27.6	32.3	37.2	55.1	47.1	40.8	33.1	30.7	26.9	67.2	74.4	83.3
Emami	152	326	BUY	468	11.0	13.0	14.7	29.6	25.2	22.2	20.0	17.6	15.4	21.5	26.5	32.0
Jub. Food	201	1,523	BUY	2,134	24.1	33.2	42.1	63.2	45.9	36.1	32.4	28.5	22.1	45.8	35.5	25.8
United Spirits	456	627	BUY	737	10.2	12.6	16.4	61.3	49.8	38.3	35.4	29.1	24.6	15.8	18.4	21.6
Radico Khaitan	42	312	BUY	496	14.1	17.8	21.5	22.1	17.5	14.5	12.8	11.3	9.5	11.5	13.8	15.3

Source: HDFC sec Inst Research



Income Statement

(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Net Revenues	63,222	73,336	77,799	86,667	95,803
Growth (%)	6.8	16.0	6.1	11.4	10.5
Material Expenses	33,482	39,956	36,940	44,019	48,763
Employee Expense	4,222	4,666	5,176	5,641	6,149
ASP Expense	5,856	6,589	7,811	8,650	9,515
Distribution Expense	2,408	2,933	3,112	3,467	3,832
Other Expenses	5,877	6,383	8,929	6,716	7,165
EBITDA	11,378	12,809	15,831	18,173	20,378
EBITDA Growth (%)	(1.9)	12.6	23.6	14.8	12.1
EBITDA Margin (%)	18.0	17.5	20.3	21.0	21.3
Adjusted EBITDAM (IND AS 116)	18.0	17.5	19.7	20.4	20.8
Depreciation	891	964	1,400	1,534	1,669
EBIT	10,487	11,845	14,431	16,638	18,709
Other Income (Including EO Items)	846	1,028	1,278	1,608	1,996
Interest	162	238	510	417	208
PBT	11,171	12,635	15,200	17,829	20,496
Total Tax	2,896	1,284	3,752	4,457	5,124
Minority Interest & Share of JVs	131	170	153	131	118
RPAT	8,145	11,182	11,294	13,241	15,254
Adjusted PAT	8,142	9,309	11,247	13,241	15,254
APAT Growth (%)	1.4	14.3	20.8	17.7	15.2
Adjusted EPS (Rs)	6.31	7.21	8.71	10.26	11.82
EPS Growth (%)	1.4	14.3	20.8	17.7	15.2

Source: Company, HDFC sec Inst Research

Balance Sheet

=>// 0				
FY18	FY19	FY20E	FY21E	FY22E
1,291	1,291	1,291	1,291	1,291
24,138	27,088	30,855	35,118	40,647
25,429	28,379	32,145	36,409	41,938
125	295	448	579	697
1,224	1,721	1,521	1,321	1,121
1,869	1,769	1,569	1,369	1,169
3,093	3,490	3,090	2,690	2,290
202	(1,760)	(1,760)	(1,760)	(1,760)
192	221	254	292	336
29,041	30,625	34,178	38,210	43,501
11,103	11,720	11,620	11,586	11,417
268	450	450	450	450
190	221	234	261	288
656	656	656	656	656
12,218	13,047	12,960	12,953	12,811
15,109	14,110	16,601	18,482	20,435
3,406	5,170	4,123	4,507	4,982
2,561	3,150	3,342	3,723	4,115
7,429	9,344	11,978	15,134	19,588
28,505	31,774	36,045	41,846	49,120
8,217	9,440	9,527	10,675	11,827
3,465	4,756	5,300	5,913	6,603
11,682	14,196	14,827	16,588	18,430
16,823	17,578	21,218	25,258	30,690
29,041	30,625	34,178	38,210	43,501
	24,138 25,429 125 1,224 1,869 3,093 202 192 29,041 11,103 268 190 656 12,218 15,109 3,406 2,561 7,429 28,505 8,217 3,465 11,682 16,823	1,291 1,291 24,138 27,088 25,429 28,379 125 295 1,224 1,721 1,869 1,769 3,093 3,490 202 (1,760) 192 221 29,041 30,625 11,103 11,720 268 450 190 221 656 656 12,218 13,047 15,109 14,110 3,406 5,170 2,561 3,150 7,429 9,344 28,505 31,774 8,217 9,440 3,465 4,756 11,682 14,196 16,823 17,578	1,291 1,291 1,291 24,138 27,088 30,855 25,429 28,379 32,145 125 295 448 1,224 1,721 1,521 1,869 1,769 1,569 3,093 3,490 3,090 202 (1,760) (1,760) 192 221 254 29,041 30,625 34,178 11,103 11,720 11,620 268 450 450 190 221 234 656 656 656 12,218 13,047 12,960 15,109 14,110 16,601 3,406 5,170 4,123 2,561 3,150 3,342 7,429 9,344 11,978 28,505 31,774 36,045 8,217 9,440 9,527 3,465 4,756 5,300 11,682 14,196 14,827	1,291 1,291 1,291 1,291 24,138 27,088 30,855 35,118 25,429 28,379 32,145 36,409 125 295 448 579 1,224 1,721 1,521 1,321 1,869 1,769 1,569 1,369 3,093 3,490 3,090 2,690 202 (1,760) (1,760) (1,760) 192 221 254 292 29,041 30,625 34,178 38,210 11,103 11,720 11,620 11,586 268 450 450 450 190 221 234 261 656 656 656 656 12,218 13,047 12,960 12,953 15,109 14,110 16,601 18,482 3,406 5,170 4,123 4,507 2,561 3,150 3,342 3,723 7,429 9,344 11,978 15,134 28,505 31,774 36,045 41



INSTITUTIONAL RESEARCH

Cash Flow Statement


(Rs mn)	FY18	FY19	FY20E	FY21E	FY22E
Reported PBT	11,170	12,635	15,200	17,829	20,496
Non-operating & EO Items	(329)	(1,873)	-	-	-
Interest Expenses	(174)	238	510	417	208
Depreciation	891	964	1,400	1,534	1,669
Working Capital Change	(3,065)	2,107	(2,505)	(2,384)	(2,478)
Tax Paid	(2,949)	(1,284)	(3,752)	(4,457)	(5,124)
OPERATING CASH FLOW (a)	5,544	12,788	10,852	12,939	14,771
Capex	(1,231)	(1,763)	(1,300)	(1,500)	(1,500)
Free Cash Flow (FCF)	4,313	11,025	9,552	11,439	13,271
Investments	1,047	-	-	-	-
Non-operating Income	353	(1,992)	(13)	(27)	(27)
INVESTING CASH FLOW (b)	169	(3,755)	(1,313)	(1,527)	(1,527)
Debt Issuance/(Repaid)	692	397	(400)	(400)	(400)
Interest Expenses	(162)	(238)	(510)	(417)	(208)
FCFE	6,243	9,192	8,628	10,595	12,635
Share Capital Issuance	0	(0)	-	(0)	0
Dividend	(6,357)	(6,358)	(7,481)	(8,977)	(9,725)
Others	152	29	33	38	44
FINANCING CASH FLOW (c)	(5,675)	(6,170)	(8,358)	(9,756)	(10,290)
NET CASH FLOW (a+b+c)	38	2,863	1,180	1,656	2,954
EO Items, Others	397	-	-	-	-
Closing Cash & Equivalents	2,001	4,864	5,998	7,654	10,608

Source: Company, HDFC sec Inst Research

Key Ratios

FY18 FY19 FY20E FY21E PROFITABILITY (%) GPM 47.0 45.5 52.5 49.2 EBITDA Margin 18.0 17.5 20.3 21.0 EBIT Margin 16.6 16.2 18.5 19.2	49.1 21.3 19.5 15.9
GPM 47.0 45.5 52.5 49.2 EBITDA Margin 18.0 17.5 20.3 21.0 EBIT Margin 16.6 16.2 18.5 19.2	21.3 19.5
EBITDA Margin 18.0 17.5 20.3 21.0 EBIT Margin 16.6 16.2 18.5 19.2	21.3 19.5
EBIT Margin 16.6 16.2 18.5 19.2	19.5
· ·	
	15 0
APAT Margin 12.9 12.7 14.5 15.3	15.9
RoE 33.4 34.6 37.2 38.6	38.9
RoIC (or Core RoCE) 40.6 48.8 47.5 52.9	57.7
RoCE 30.5 31.5 34.7 36.5	37.0
EFFICIENCY	
Tax Rate (%) 25.9 10.2 24.7 25.0	25.0
Fixed Asset Turnover (x) 4.9 5.1 5.0 5.1	5.1
Inventory (days) 87.2 70.2 77.9 77.8	77.9
Debtors (days) 19.7 25.7 19.3 19.0	19.0
Other Current Assets (days) 14.8 15.7 15.7	15.7
Payables (days) 47.4 47.0 44.7 45.0	45.1
Other Current Liab & Provns (days) 20.0 23.7 24.9 24.9	25.2
Cash Conversion Cycle (days) 54.2 41.0 43.3 42.6	42.3
Net D/E (x) (0.2) (0.3) (0.3)	(0.4)
Interest Coverage (x) 0.02 0.02 0.04 0.03	0.01
PER SHARE DATA (Rs)	
EPS 6.3 7.2 8.7 10.3	11.8
CEPS 7.0 8.0 9.8 11.4	13.1
Dividend 4.2 5.0 6.0 6.5	7.0
Book Value 19.7 22.0 24.9 28.2	32.5
VALUATION	
P/E (x) 62.6 54.8 45.3 38.5	33.4
P/BV (x) 20.1 18.0 15.9 14.0	12.2
EV/EBITDA (x) 44.9 39.7 32.0 28.1	25.1
EV/Revenues (x) 8.1 6.9 6.5 5.9	5.3
OCF/EV (%) 1.1 2.5 2.1 2.5	2.9
FCF/EV (%) 1.1 1.8 1.9 2.2	2.6
FCFE/Mkt Cap (%) 1.2 1.8 1.7 2.1	2.5
Dividend Yield (%) 1.1 1.3 1.5 1.6	1.8

RECOMMENDATION HISTORY



Date	CMP	Reco	Target	
10-Oct-18	295	BUY	392	
2-Nov-18	320	BUY	380	
9-Jan-19	382	BUY	394	
10-Apr-19	356	BUY	402	
7-May-19	340	BUY	386	
9-Jul-19	370	BUY	384	
2-Aug-19	363	BUY	395	
22-Sep-19	379	NEU	395	
11-Oct-19	385	NEU	400	
27-Oct-19	393	NEU	391	

Rating Definitions

BUY : Where the stock is expected to deliver more than 10% returns over the next 12 month period

NEUTRAL : Where the stock is expected to deliver (-)10% to 10% returns over the next 12 month period

SELL : Where the stock is expected to deliver less than (-)10% returns over the next 12 month period

HDFC securities Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171 7330 www.hdfcsec.com



INSTITUTIONAL RESEARCH

Disclosure:

We, **Naveen Trivedi**, **MBA & Siddhant Chhabria**, **PGDBM**, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest.

Any holding in stock -No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: HDF 2806925/HDF C000222657; SEBI Research Analyst Reg. No.: INH000002475: SEBI Investment Adviser Reg. No.: INA000011538: CIN - U67120MH2000PLC152193

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.